Dale Allison
Family Medicine · Waco, TXNPI 1154393429
Payments from drug & device makers
Across 3,554 payments — averaging $647.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$988K
- Alnylam Pharmaceuticals Inc.$299K
- AbbVie$278K
- CSL Behring$205K
- Sanofi US Services Inc.$188K
- AstraZeneca$143K
- plus $201K from 25 others
Across 62 payments — averaging $603.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glenmark Pharmaceuticals Inc., USA$24K
- Novo Nordisk$6K
- Ichnos Glenmark Innovation Inc$4K
- Novo Nordisk AS$3K
What the payments were for
- Consulting fees$18,44038%
- Speaking & faculty fees$6191%
- Travel & lodging$27,14656%
- Food & beverage$2,5155%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 2,448 | $988,413 |
| Alnylam Pharmaceuticals Inc. | 756 | $298,641 |
| AbbVie(2 entities) | 65 | $277,697 |
| CSL Behring | 92 | $205,110 |
| Sanofi US Services Inc. | 62 | $188,158 |
| AstraZeneca | 8 | $142,812 |
| Novartis | 2 | $55,717 |
| Kowa Research Institute, Inc. | 28 | $43,382 |
| Galderma Laboratories, L.p. | 7 | $23,392 |
| Novo Nordisk | 26 | $20,201 |
| Bayer | 14 | $17,100 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16,864 |
| Boehringer Ingelheim International GmbH | 2 | $14,086 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $9,759 |
| Dexcom, Inc. | 7 | $103 |
| Medtronic | 1 | $85 |
| GSK | 5 | $73 |
| Amarin Pharma, Inc. | 5 | $68 |
| Johnson & Johnson | 3 | $42 |
| Shire North American Group Inc | 3 | $39 |
| Merck | 3 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Amgen(2 entities) | 2 | $33 |
| Radius Health, Inc. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$1,220
- UBRELVY$750
How this compares
$2,301,999 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 30 | $826 |
| Warfarin Sodium | 25 | $279 |
| Losartan Potassium | 13 | $237 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Waco
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.